Actively Recruiting
Innovative Drug Delivery Nanophotonic Platform for Implementation of Sarcoma Therapy
Led by Istituto Ortopedico Rizzoli · Updated on 2025-09-22
30
Participants Needed
2
Research Sites
104 weeks
Total Duration
On this page
Sponsors
I
Istituto Ortopedico Rizzoli
Lead Sponsor
U
Università Degli Studi del Sannio Dipartimento di Ingegneria Benevento
Collaborating Sponsor
AI-Summary
What this Trial Is About
DEEPLY aims to improve sarcoma therapy by the development of an innovative nanophotonic delivery approach to be applied in the future as an integrated local therapy for patients with inoperable tumors or with oligometastases. The major aim of the project is the development of innovative nanocarriers loaded with chemotherapeutic agents, whose delivery will be improved by the use of an optic fiber (optoporation). After the synthesis, and characterization of NPs, a prototype will be produced and preclinically validated on patient-derived biological material. This wide comprehensive methodological approach will ensure the obtainment of robust data to be faster exploited toward clinical applications.
CONDITIONS
Official Title
Innovative Drug Delivery Nanophotonic Platform for Implementation of Sarcoma Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 0 to 85 years undergoing surgery or biopsy for soft tissue sarcomas (STSs) or bone sarcomas (BSs), including osteosarcomas
- Patients may have received or be receiving chemotherapy, targeted therapy, radiotherapy, or combination therapy
- Only adult patients (older than 18 years) will be enrolled by IRST
- Signed informed consent from all enrolled patients; IOR patients must sign both project and biobank consent forms
You will not qualify if you...
- Patients without soft tissue sarcomas or bone sarcomas
- Patients with multiple primary tumors
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Istituto Ortopedico Rizzoli-OSOTT
Bologna, Emilia-Romagna, Italy, 40136
Actively Recruiting
2
IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori
Meldola, Emilia-Romagna, Italy, 47014
Actively Recruiting
Research Team
T
Toni Ibrahim, MD Oncologist
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here